Bitwise Crypto Industry Innovators ETF (ARCA: BITQ)

Dernières nouvelles pour Bitwise Crypto Industry Innovators ETF (ARCA:BITQ)

Bitwise Crypto Industry Innovators ETF

Technology

Financial Services

Other

Healthcare

Consumer Cyclical

The Fund invests in securities comprising the Index and in depositary receipts representing securities of the Index. The Index was designed by Bitwise Index Services, LLC (the Index Sponsor) to measure the performance of companies involved in servicing the cryptocurrency markets, including crypto mining firms, crypto mining equipment suppliers, crypto financial services companies, or other financial institutions servicing primarily crypto-related clientele (i.e., the crypto ecosystem). Under normal circumstances, the Fund invests at least 80 percent of its net assets (plus the amount of borrowings for investment purposes) in securities of Crypto Innovators.

Marathon Patent Group Inc.

Coinbase Global, Inc.

Microstrategy Inc

Terawulf Inc

Northern Data Ag

Iris Energy Ltd

Core Scientific Inc Common Stock

Cipher Mining Inc

Cleanspark Inc.

Galaxy Digital Holdings Ltd

Invesco Government & Agency Portfolio, Institutional Class

Northern Data

Galaxy Digital Holdi

Riot Blockchain Inc.

Applied Digital Corp

Bitdeer Technologies Group

ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.62 by 11.29 percent. This is a 13.11 percent increase over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $268.08 million which beat the analyst consensus estimate of $260.69 million by 2.83 percent. This is a 26.67 percent increase over sales of $211.63 million the same period last year.

Earnings

Earnings Beats

News

ODDITY Tech Q1 Adj. EPS $0.69 Beats $0.62 Estimate, Sales $268.08M Beat $260.69M Estimate

ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy
First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling

Biotech

Events

General

ERAS

Erasca Presents New Preclinical Data For Profiles Of RAS-Targeting Franchise At 2025 AACR Annual Meeting

<a href="https://www.fanniemae.com/about-us/investor-relations/monthly-summary" title="https://www.fanniemae.com/about-us/investor-relations/monthly-summary">https://www.fanniemae.com/about-us/investor-relations/monthly-summary</a>

FNMA

Fannie Mae Releases March 2025 Monthly Summary

ProsperaHeart with donor quantity score (DQS) demonstrates significant correlation with clinical outcomes
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54246141&amp;newsitemid=20250429528308&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=256696dd468270ee171db9cc0e8d0e19">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, announced the results of its DEFINE-HT clinical trial in heart transplantation, which were shared today, April 29, 2025, in an oral presentation at the International Society for Heart and Lung Transplantation 45th Annual Meeting in Boston, MA.
DEFINE-HT is the first prospective, multicenter study in heart transplant recipients designed to assess whether elevated levels of donor-derived cell-free DNA (dd-cfDNA), as measured by Prospera Heart with DQS, are associated with adverse clinical outcomes. Following heart transplant, Prospera testing was performed concurrently with rejection surveillance monitoring, including endomyocardial biopsies (EMB), for up to one year.
Findings from the study, which included more than 1,100 dd-cfDNA samples, demonstrated that dd-cfDNA significantly correlated with adverse outcomes, a composite endpoint defined as the total number of treated rejections, graft dysfunctions, re-transplantations, and deaths at one year after heart transplant.

NTRA

Natera: Results Of DEFINE-HT Clinical Trial Shows Prospera Heart Is Predictive Of Clinical Outcomes And Outperforms Biopsy In Predicting Graft Dysfunction

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) is looking for Q2 Adj EPS of $0.30-$0.70 vs $0.40 analyst estimate. sees sales of $190.000 million-$205.000 million vs $197.03 million analyst estimate.

Guidance

Rogers Sees Q2 Adj EPS $0.30-$0.70 vs $0.40 Est; Sees Sales $190.000M-$205.000M vs $197.03M Est

Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.28 by 28.57 percent. This is a 44 percent increase over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $239.14 million which beat the analyst consensus estimate of $233.74 million by 2.31 percent. This is a 10.73 percent increase over sales of $215.96 million the same period last year.

TENB

Tenable Holdings Q1 Adj. EPS $0.36 Beats $0.28 Estimate, Sales $239.14M Beat $233.74M Estimate

Ribbon Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) sees Q2 sales of $210.000 million-$220.000 million vs $209.94 million analyst estimate.

RBBN

Ribbon Communications Sees Q2 Sales $210.000M-$220.000M vs $209.94M Est

Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) reported quarterly earnings of $1.90 per share which missed the analyst consensus estimate of $2.09 by 9.09 percent. This is a 475.76 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $2.16 billion which missed the analyst consensus estimate of $2.31 billion by 6.36 percent. This is a 30.51 percent increase over sales of $1.66 billion the same period last year.

Earnings Misses

Seagate Tech Hldgs Q3 Adj. EPS $1.90 Misses $2.09 Estimate, Sales $2.16B Miss $2.31B Estimate

LendingClub (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.11 by 9.09 percent. This is a 9.09 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $217.71 million which beat the analyst consensus estimate of $214.30 million by 1.59 percent. This is a 20.49 percent increase over sales of $180.69 million the same period last year.

LendingClub Q1 EPS $0.10 Misses $0.11 Estimate, Sales $217.71M Beat $214.30M Estimate

Clearwater Paper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.04) by 850 percent. This is a 136.89 percent decrease over earnings of $1.03 per share from the same period last year. The company reported quarterly sales of $378.20 million which missed the analyst consensus estimate of $387.00 million by 2.27 percent. This is a 23.78 percent decrease over sales of $496.20 million the same period last year.

Clearwater Paper Q1 EPS $(0.38) Misses $(0.04) Estimate, Sales $378.20M Miss $387.00M Estimate

AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) raises FY2025 Adj EPS guidance from $(0.64)-$(0.57) to $(0.55)-$(0.50) vs $(0.66) analyst estimate. Affirms FY2025 sales outlook from $517.00 million-$527.00 million to $517.00 million-$527.00 million vs $522.79 million estimate.

ATRC

AtriCure Raises FY2025 Adj EPS Guidance from $(0.64)-$(0.57) to $(0.55)-$(0.50) vs $(0.66) Est; Affirms FY2025 Sales Guidance of $517.00M-$527.00M vs $522.79M Est

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.25 by 8 percent. This is a 53.45 percent decrease over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $190.50 million which beat the analyst consensus estimate of $186.33 million by 2.24 percent. This is a 10.73 percent decrease over sales of $213.40 million the same period last year.

Rogers Q1 Adj. EPS $0.27 Beats $0.25 Estimate, Sales $190.50M Beat $186.33M Estimate

UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) reported quarterly earnings of $2.58 per share which beat the analyst consensus estimate of $2.19 by 17.81 percent. This is a 4.45 percent increase over earnings of $2.47 per share from the same period last year. The company reported quarterly sales of $563.84 million which beat the analyst consensus estimate of $559.01 million by 0.86 percent. This is a 41.43 percent increase over sales of $398.68 million the same period last year.

UMBF

UMB Financial Q1 Adj. EPS $2.58 Beats $2.19 Estimate, Sales $563.84M Beat $559.01M Estimate

SOND

Sonder Holdings Receives Deficiency Letter From Nasdaq Related To Delayed Filing Of Annual Report On Form 10-K

Huron Consulting Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURN#NASDAQ">HURN</a>) affirms FY2025 Adj EPS guidance from $6.80-$7.60 to $6.80-$7.60 vs $7.16 analyst estimate. Affirms FY2025 sales outlook from $1.58 billion-$1.66 billion to $1.58 billion-$1.66 billion vs $1.62 billion estimate.

HURN

Huron Consulting Gr Affirms FY2025 Adj EPS Guidance of $6.80-$7.60 vs $7.16 Est; Affirms FY2025 Sales Guidance of $1.58B-$1.66B vs $1.62B Est

Ribbon Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.01 by 400 percent. This is a 200 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $181.00 million which missed the analyst consensus estimate of $191.66 million by 5.56 percent. This is a 0.74 percent increase over sales of $179.66 million the same period last year.

Ribbon Comms Q1 Adj. EPS $(0.03) Misses $0.01 Estimate, Sales $181.00M Miss $191.66M Estimate

Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.66 by 12.12 percent. This is a 22.11 percent decrease over earnings of $0.95 per share from the same period last year. The company reported quarterly sales of $9.31 billion which missed the analyst consensus estimate of $9.32 billion by 0.12 percent. This is a 0.25 percent increase over sales of $9.29 billion the same period last year.

MDLZ

Mondelez International Q1 Adj. EPS $0.74 Beats $0.66 Estimate, Sales $9.31B Miss $9.32B Estimate

PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) affirms FY2025 Adj EPS guidance from $7.75-$8.05 to $7.75-$8.05 vs $7.81 analyst estimate..

PPG Indus Affirms FY2025 Adj EPS Guidance of $7.75-$8.05 vs $7.81 Est

<ul>
<li>The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%. &nbsp;</li>
<li>Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week maintenance data on track for Q2 2026 and, if successful, NDA submission planned for H2 2026. &nbsp;</li>
<li>Blinded baseline characteristics align with pre-specified target population and are consistent with Phase 2b UC trial participant characteristics &nbsp;</li>
<li>Cash runway through ABTECT induction trials readout and into Q4 2025 &nbsp;</li>
</ul>
PARIS, France – April 29, 2025 – 10:05 PM CET – Abivax SA (PARIS:<a class="ticker" href="https://www.benzinga.com/stock/FR#PARIS">FR</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the completion of enrollment for the Phase 3 ABTECT trials in patients with moderately to severely active ulcerative colitis.

ABVX

PARIS:FR

Abivax Completes Enrollment For Phase 3 ABTECT Trials In Patients With Moderately To Severely Active Ulcerative Colitis

Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) reported quarterly earnings of $2.76 per share which beat the analyst consensus estimate of $2.68 by 2.99 percent. This is a 9.96 percent increase over earnings of $2.51 per share from the same period last year. The company reported quarterly sales of $9.59 billion which beat the analyst consensus estimate of $9.55 billion by 0.46 percent. This is a 9.33 percent increase over sales of $8.78 billion the same period last year.

Comments

Bitwise Crypto Industry Innovators ETF

Actualités

Dernières nouvelles pour Bitwise Crypto Industry Innovators ETF (ARCA:BITQ)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL